Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 4/20 | 0.53 |
| ▸ | SLC10A6 | Q3KNW5 | 3/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.51 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.51 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.50 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CCR2 | P41597 | 2/20 | 0.46 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492112 | 0.83 | SLC10A6 (0.56) | CCR9SLC10A6SLC20A2SLC20A1SLC10A2 | |
| SCHEMBL5125728 | 0.83 | SLC10A6 (0.61) | CCR9SLC10A6KDM1ASLC20A2SLC20A1 | |
| SCHEMBL492036 | 0.81 | CCR2 (0.57) | CCR9SLC10A6KDM1ASLC20A2SLC20A1 | |
| SCHEMBL5110439 | 0.81 | SLC20A2 (0.59) | CCR9SLC10A6KDM1ASLC20A2SLC20A1 | |
| SCHEMBL492269 | 0.81 | METAP2 (0.63) | CCR9SLC10A6SLC10A2SLC10A1LMNA | |
| SCHEMBL5115424 | 0.78 | SLC20A2 (0.66) | CCR9SLC10A6KDM1ASLC20A2SLC20A1 | |
| SCHEMBL5115526 | 0.78 | KCNA5 (0.61) | CCR9SLC10A6SLC20A2SLC20A1SLC10A2 | |
| SCHEMBL492242 | 0.77 | GPR27 (0.57) | CCR9SLC10A6SLC10A2SLC10A1LMNA | |
| SCHEMBL492066 | 0.76 | SLC10A6 (0.55) | CCR9SLC10A6SLC10A2SLC10A1LMNA | |
| SCHEMBL21384562 | 0.76 | AVPR2 (0.59) | CCR9SLC10A6KDM1ASLC20A2SLC20A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541410-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2012-05-03 | — | — | US | disclosed |
| US-8106213-B2 | For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080096936-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | TELEVOX SOFTWARE, INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-7326789-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-05 | — | — | US | disclosed |
| EP-1614678-A2 | Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them | Sanofi-Aventis Deutschland GmbH (DE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1095016-B1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-6881735-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-19 | — | — | US | disclosed |
| US-20040186145-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2004-09-23 | — | — | US | disclosed |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-05-23 | — | — | US | disclosed |
| US-6335334-B1 | HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | disclosed |
| EP-1095016-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002851-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | GUCY1A1, GUCY1B1, GUCY1A2 | CCR9 3361/4885SLC10A6 1785/4885KDM1A 2960/4885 |
| US-20040186145-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1B1, GUCY1A2 | CCR9 2317/4885SLC10A6 2557/4885KDM1A 2921/4885 |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1B1, GUCY1A2 | CCR9 2317/4885SLC10A6 2557/4885KDM1A 2921/4885 |
| US-20080096936-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1A2, GUCY1B1 | CCR9 3278/4885SLC10A6 1841/4885KDM1A 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.